Get the Stockscreener App
0.4349
0.25%
-0.0011
Oragenics Inc stock is traded at $0.4349, with a volume of 32,733.
It is down -0.25% in the last 24 hours and down -13.02% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.436
Open:
$0.4538
24h Volume:
32,733
Relative Volume:
1.39
Market Cap:
$1.96M
Revenue:
$7,500
Net Income/Loss:
$-9.83M
P/E Ratio:
-0.0711
EPS:
-6.1164
Net Cash Flow:
$-9.33M
1W Performance:
-4.63%
1M Performance:
-13.02%
6M Performance:
-36.05%
1Y Performance:
-66.55%
1-Day Range:
$0.43
$0.4538
1-Week Range:
$0.43
$0.4625
52-Week Range:
$0.43
$1.45
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.4349 | 1.96M | 7,500 | -9.83M | -9.33M | -6.1164 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oragenics Inc Stock (OGEN) Latest News
Oragenics (OGEN) Edges Higher as Sub-$1 Biotech Holds Near $0.50Iron Condor Alert - https://www.siam.in/
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum - GlobeNewswire
Oragenics Faces NYSE Compliance Challenges Amid Trial Progress - The Globe and Mail
Oragenics Faces Potential NYSE American Delisting on Equity Shortfall - minichart.com.sg
Oragenics Faces NYSE Compliance Challenges Amid Trial Progress - TipRanks
Oragenics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Oragenics (NYSE: OGEN) faces NYSE listing warning as equity falls short - Stock Titan
Oragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing Status - Quiver Quantitative
Oragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing Status - Quiver Quantitative
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update - GlobeNewswire
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update - Yahoo Finance
Oragenics (OGEN) Earnings Report: EPS Exceeds Its Estimate for the Current Session; Trading Response - dars.gov.et
Oragenics (OGEN) Earnings Report: EPS Exceeds Its Estimate for the Current Session; Trading Response - careplusvn.com
Oragenics (OGEN) Earnings Report: EPS Exceeds Its Estimate for the Current Session; Trading Response - www.dars.gov.et
Oragenics (OGEN) Earnings Report: EPS Exceeds Its Estimate for the Current Session; Trading Response - dars.gov.et
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineRange Breakout - vinanet.vn
Oragenics: Q2 Earnings Snapshot - AOL.com
Oragenics: Q2 Earnings Snapshot - 10TV
Oragenics (OGEN) flags going concern risk with $4.7M loss and $3.9M cash - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineRange Breakout - vinanet.vn
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineAAII Bullish - www.dars.gov.et
Oragenics (OGEN) Gains 2% as Micro-Cap Biotech Holds Key Support at $0.47Technical Analysis - vinanet.vn
Oragenics (OGEN) Gains 2% as Micro-Cap Biotech Holds Key Support at $0.47Collar Trade - dars.gov.et
OGEN Q2 2023 Earnings: Narrower EPS Beat Lifts Shares 2.0%Earnings Beat Streak - careplusvn.com
OGEN Q2 2023 Earnings: Narrower EPS Beat Lifts Shares 2.0%Interim Report - vinanet.vn
Oragenics Q2 2023 Earnings: Narrowed Loss Surprises as Operational Efficiency ImprovesEarnings Acceleration Picks - careplusvn.com
Oragenics Q2 2023 Earnings: Narrowed Loss Surprises as Operational Efficiency ImprovesEBITDA Analysis - vinanet.vn
Oragenics Q2 2023 Earnings: Narrowed Loss Surprises as Operational Efficiency ImprovesPre-Earnings Setup - dars.gov.et
Oragenics Inc. Revenue Breakdown – AMEX:OGEN - TradingView
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Cash Flow - TradingKey
OGEN|Oragenics Inc|Price:0.507|Chg%:-0.004 - TradingKey
TradingKey - TradingKey
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
OGEN Q2 2023 Earnings: EPS Surprises to the Upside Despite No RevenueRevenue Guidance Update - vinanet.vn
OGEN Q2 2023 Earnings: EPS Surprises to the Upside Despite No RevenueOperating Income Trends - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesPost-Earnings Drift - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesNew Analyst Coverage - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesFull Year Guidance - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesCost Structure Review - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesEPS Revision Trend - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesOperating Income Trends - dars.gov.et
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineBPI Bear Correction - dars.gov.et
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineVOLD Alert - careplusvn.com
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineTechnical Analysis - vinanet.vn
OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Despite Stock DeclineGuidance vs Actual - vinanet.vn
OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Despite Stock DeclineEarnings Revision Downgrade - www.dars.gov.et
Oragenics Incto Receive Exclusive License - Moomoo
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oragenics Inc Stock (OGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Frederick W. Telling | Director |
Dec 12 '25 |
Proposed Sale |
0.91 |
210 |
192 |
0 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):